Lupin launches Atorvastatin Calcium tablets post regulator nod

Pharma major, Lupin Limited, today announced that the company has launched Atorvastatin Calcium tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg after receiving approval from United States Food & Drug Administration (USFDA). The product will be manufactured at the company's Nagpur facility in India.  

Atorvastatin Calcium tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, is a generic equivalent of Lipitor tablets, 10 mg, 20 mg, 40 mg, and 80 mg, of Pfizer Inc. The said drug is indicated to lower cholesterol in the blood for adults and children over 10 years of age. Atorvastatin is also prescribed to lower the risk of heart attack and stroke in patients with cardiovascular diseases, diabetes, and other risk factors such as eye problems, kidney diseases, or high blood pressure.

According to July 2020 MAT data from IMS Health (IQVIA), Atorvastatin Calcium tablets USP had annual sales of approximately USD 559 million in the US.

Headquartered in Mumbai, Lupin is an innovation-led transnational pharmaceutical company that develops and commercialises a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

At 2.20 pm on Monday, the stock of Lupin Limited was trading at Rs 1,009.45 per share, up by 1.17 per cent or Rs 11.65 per share on BSE, against a 1.54 per cent gain in the benchmark index. The 52-week high is recorded at Rs 1,121.85 and the 52-week low is Rs 505 on BSE.